Provided herein are methods for decreasing blood brain barrier permeability in a subject with neuroinflammatory disorder comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin B1 receptor.